Rare genetic cause of hypertension

Orphanet code 156629 refers to a rare genetic cause of hypertension, which encompasses a group of monogenic disorders that lead to elevated blood pressure through specific genetic mutations affecting renal sodium handling, aldosterone regulation, or vascular tone. These conditions are distinct from the far more common essential (primary) hypertension and include entities such as familial hyperaldosteronism, Liddle syndrome, Gordon syndrome (pseudohypoaldosteronism type 2), apparent mineralocorticoid excess, and glucocorticoid-remediable aldosteronism, among others. Each of these disorders disrupts normal blood pressure regulation through different molecular mechanisms, but they share the common feature of early-onset or treatment-resistant hypertension that has a clear hereditary basis. The body systems primarily affected include the cardiovascular system (through sustained elevated blood pressure leading to end-organ damage such as left ventricular hypertrophy, stroke, and retinopathy) and the renal system (through abnormal electrolyte handling, particularly sodium retention and potassium wasting or retention depending on the specific condition). Patients may present with hypertension in childhood or young adulthood, often with a strong family history. Associated features can include hypokalemia or hyperkalemia, metabolic alkalosis or acidosis, and suppressed or elevated renin and aldosterone levels, depending on the underlying genetic defect. Treatment depends on the specific genetic diagnosis. Some forms respond to targeted therapies — for example, glucocorticoid-remediable aldosteronism responds to low-dose dexamethasone, Liddle syndrome responds to amiloride or triamterene, and apparent mineralocorticoid excess may respond to spironolactone. Accurate genetic diagnosis is essential for guiding appropriate therapy and avoiding ineffective or harmful treatments. Genetic counseling is recommended for affected families.

Common questions about Rare genetic cause of hypertension